Drug Profile
Aripiprazole controlled release - Zysis
Alternative Names: LAO Aripiprazole OW; ZY 102Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Zysis
- Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor agonists; Serotonin 7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Bipolar disorders; Schizophrenia
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Bipolar-disorders in Europe (PO, Controlled release)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Schizophrenia in Europe (PO, Controlled release)
- 16 Feb 2016 Aripiprazole controlled release is still available for partnering (http://www.zysis.com/wp-content/uploads/2015/07/LAO-Aripiprazole-slide-deck.pdf)